Pushing the boundary of immune therapeutic discovery
The immune system holds the key to unlocking an ocean of new targets & therapies — but current discovery technologies only scratch the surface...
Using a proprietary synthesis of innovations in genomic technology & data science, Avail’s discovery platform dives deeper to translate novel targets into de-risked therapeutic assets, with unprecedented scalability and efficiency
our investors
